Who is Baysient?
Baysient creates cloud-based software to facilitate individualized dosing of anti-inflammatory MAbs to improve outcomes in patients with inflammatory diseases like IBD. Baysient’s software utilizes a pioneering Compuceutical approach with Bayesian models, routine lab results and demographic information to allow physicians to individualize dosing to a specific target trough level.
Why Baysient?
How Does It Work?
Schedule a Demo
Interested in how iDose can improve your patient outcomes?
Diane R. Mould, PhD
Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.
Latest Blog Post
Unlocking Better Outcomes with Vedolizumab: The Power of Therapeutic Drug Monitoring in Pediatric IBD
Despite significant advancements in biologic therapy for pediatric inflammatory bowel disease (IBD), loss of response (LOR) remains a major challenge in clinical management. Infliximab (IFX) and Vedolizumab (VEDO), both widely used monoclonal antibodies, offer disease-modifying benefits, yet many pediatric patients fail to achieve or sustain…
